01—Abstract
Summary
Summary of the 10-Q filed April 22, 2025. Cited figures are marked; the original filing is the authoritative source.
Medpace Holdings, Inc. reported first-quarter 2025 revenue, net of $558.6 milliona, up from $511.0 million in the prior-year quarter, with net income of $114.6 million compared to $102.6 million.
Income from operations was $113.5 millionb versus $104.1 million. Diluted earnings per share were $3.67, compared with $3.20 a year earlier. Growth was primarily driven by the Metabolic, Oncology, and Central Nervous System therapeutic areas.
Selling, general and administrative expenses rose to $57.9 millionc from $44.1 million, attributed to higher personnel costs. Net new business awards were $500.0 million versus $615.6 million, and backlog was $2,846.0 million, down 2.1% from $2,907.1 million a year earlier. Capital allocation was the dominant balance sheet event.
The company repurchased 1,193,011 shares for $389.8 milliond during the quarter, and cash and cash equivalents fell to $441.4 million from $669.4 million at December 31, 2024. Shareholders' equity declined to $593.6 million from $825.5 million, and the accumulated deficit was $(269.7) million versus retained earnings of $8.2 million at year-end 2024. The company had no indebtedness at March 31, 2025.
On April 17, 2025, the Board approved an additional $1.0 billion repurchase increase, and on April 18, 2025, the credit facility was amended to increase the line of credit to up to $600.0 million. Operating cash flow was $125.8 million, compared with $152.7 million in the prior-year quarter.
The effective income tax rate was 3.0%, compared with 9.0% a year earlier, reflecting excess tax benefits from share-based compensation. Total performance obligations remaining were approximately $3.4 billion.
02—Key points
Key Highlights
- Revenue, net rose 9.3% to $558.6 million from $511.0 million in Q1 2024.
- Net income increased to $114.6 million from $102.6 million; diluted EPS was $3.67 versus $3.20.
- Share repurchases totaled $389.8 million for 1,193,011 shares in Q1 2025, after the Board raised the authorization by $600.0 million to $1.1 billion.
- Cash and cash equivalents declined to $441.4 million from $669.4 million at December 31, 2024, while the company had no indebtedness at March 31, 2025.
- Net new business awards were $500.0 million, down from $615.6 million, and backlog decreased 2.1% to $2,846.0 million.
- Selling, general and administrative expenses increased 31.3% to $57.9 million, primarily from higher personnel costs.
- Effective tax rate was 3.0%, down from 9.0%, driven by excess tax benefits from share-based compensation.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed April 22, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $558.57M$511.04M | +9.3% |
| SG&A Expenses | $57.90M$44.08M | +31.3% |
| Operating Expenses | $445.05M$406.98M | +9.4% |
| Operating Income | $113.52M$104.07M | +9.1% |
| Net Income | $114.59M$102.59M | +11.7% |
| EPS (Basic) | $3.77$3.32 | +13.6% |
| EPS (Diluted) | $3.67$3.20 | +14.7% |
| Shares Outstanding (Basic) | 30.39M30.84M | −1.5% |
| Shares Outstanding (Diluted) | 31.20M32.00M | −2.5% |
05—Questions
Frequently Asked Questions
How did Medpace perform financially in the first quarter of 2025?
Revenue, net was $558.6 million, up from $511.0 million a year earlier. Income from operations was $113.5 million, compared with $104.1 million, and net income was $114.6 million, compared with $102.6 million.
How much did Medpace spend on share repurchases, and what authorization remains?
The company repurchased 1,193,011 shares for $389.8 million in Q1 2025. As of March 31, 2025, remaining authorization was $344.8 million. On April 17, 2025, the Board approved an additional $1.0 billion increase to the program.
Did the company change its borrowing capacity?
Yes. On April 18, 2025, Amendment No. 8 to the Loan Agreement increased the line of credit to up to $600.0 million and extended the revolving credit note's expiration to April 30, 2027. At March 31, 2025, the company had no outstanding indebtedness under the Credit Facility.
What drove the decline in backlog and net new business awards?
The filing reports net new business awards of $500.0 million for Q1 2025, versus $615.6 million in Q1 2024, and backlog of $2,846.0 million, down $61.1 million from $2,907.1 million a year earlier. Approximately $1,600.0 million to $1,620.0 million of backlog is expected to convert to net revenue over the next twelve months.
Why did operating cash flow decline?
Operating cash flow was $125.8 million, compared with $152.7 million. The filing attributes the change in the first quarter of 2025 to a $23.2 million decrease in accrued expenses and a $17.6 million increase in prepaid expenses, partially offset by other items. In the prior-year period, advanced billings had increased by $56.8 million.
06—Continue